Immunology & Rheumatology Clinical Trials

Statistical methods in immunology & rheumatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All immunology & rheumatology trials

1,062 results

• Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367): Complete Statistical AnalysisIndependent statistical analysis of Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00442559).Phase 4Results postedn = 191NCT00442559
• Montelukast in Perennial Allergic Rhinitis – 2001-2002 Study (0476-246): Complete Statistical AnalysisIndependent statistical analysis of Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00974571).Phase 3Results postedn = 1,365NCT00974571
• MORPHEOIndependent statistical analysis of A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma: primary endpoint results, effect estimate…Phase 4Results postedn = 202NCT04502862
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 24NCT00462605
• Multi OIT to Test Immune Markers After Minimum Maintenance Dose: Complete Statistical AnalysisIndependent statistical analysis of Multi OIT to Test Immune Markers After Minimum Maintenance Dose: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03181009).Phase 2Results postedn = 60NCT03181009
• Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED): primary endpoint results, effect estimate with confidence interval,…Phase 4Results postedn = 217NCT00779116
• Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant: Complete Statistical AnalysisIndependent statistical analysis of Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 2NCT02464878
• Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 34NCT03156023
• Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL: Complete Statistical AnalysisIndependent statistical analysis of Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 22NCT05507827
• Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 35NCT02120157
• Mylan Insulin Aspart Study: Complete Statistical AnalysisIndependent statistical analysis of Mylan Insulin Aspart Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03760068).Phase 3Results postedn = 478NCT03760068
• myOpportunITy2Independent statistical analysis of A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP): primary endpoint results, effect estimate…Phase 3Results postedn = 30NCT04224688
• myOpportunITy3Independent statistical analysis of A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP): primary endpoint results, effect estimate…Phase 3Results postedn = 43NCT04596995
• N-3 PUFA and Rheumatoid Arthritis in Korea: Complete Statistical AnalysisIndependent statistical analysis of N-3 PUFA and Rheumatoid Arthritis in Korea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01618019).Phase NAResults postedn = 109NCT01618019
• NASQIndependent statistical analysis of Individualized Nutrition for Adult Recipients of Allogeneic Stem Cell Transplants - Effect on Quality of Life: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 119NCT01181076
• NAVIGATORIndependent statistical analysis of the phase 3 NAVIGATOR trial (NCT03347279) of tezepelumab 210mg Q4W versus placebo in severe uncontrolled asthma: negative binomial exacerbation rate ratios, mixed-model secondary endpoints, safety and interpretation.Phase 3Results postedn = 1,061NCT03347279
• Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: Complete Statistical AnalysisIndependent statistical analysis of Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 50NCT01515995
• NefigardIndependent statistical analysis of Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 365NCT03643965
• Neo-Synalar Modified 48 Hour Patch Test: Complete Statistical AnalysisIndependent statistical analysis of Neo-Synalar Modified 48 Hour Patch Test: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02168478).Phase 4Results postedn = 206NCT02168478
• NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test: Complete Statistical AnalysisIndependent statistical analysis of NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03522675).Phase NAResults postedn = 22NCT03522675
• Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain: Complete Statistical AnalysisIndependent statistical analysis of Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 151NCT02343003
• Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02152085).Phase NAResults postedn = 29NCT02152085
• Neuroprotection With Riluzole Patients With Early Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Neuroprotection With Riluzole Patients With Early Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00501943).Phase 2Results postedn = 43NCT00501943
• New Onset Type 1 Diabetes: Role of Exenatide: Complete Statistical AnalysisIndependent statistical analysis of New Onset Type 1 Diabetes: Role of Exenatide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01269034).Phase 4Results postedn = 13NCT01269034
• NewHopeIndependent statistical analysis of Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 151NCT01246401
• NEXUSIndependent statistical analysis of Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 108NCT02379091
• NGAM-05Independent statistical analysis of High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01313507).Phase 3Results postedn = 21NCT01313507
• NIMBLEIndependent statistical analysis of the phase 3 NIMBLE trial (NCT04718389) comparing depemokimab with mepolizumab or benralizumab in severe eosinophilic asthma, including the negative binomial exacerbation rate ratio, non-inferiority logic, ANCOVA secondary endpoints…Phase 3Results postedn = 1,717NCT04718389
• NIMBUSIndependent statistical analysis of A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple…Phase 3Results postedn = 455NCT01311687
• Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: Complete Statistical AnalysisIndependent statistical analysis of Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 130NCT00090779
• Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 20NCT04205409
• Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 78NCT03016871
• Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma: primary endpoint…Phase 2Results postedn = 100NCT02098109
• Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 126NCT02192164
• Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect: Complete Statistical AnalysisIndependent statistical analysis of Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 44NCT02772666
• nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03182374).Phase NAResults postedn = 252NCT03182374
• NUCALA® Special Drug Use Investigation (EGPA, Long-term): Complete Statistical AnalysisIndependent statistical analysis of NUCALA® Special Drug Use Investigation (EGPA, Long-term): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03557060).Phase NAResults postedn = 4,115NCT03557060
• OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE): Complete Statistical AnalysisIndependent statistical analysis of OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE): primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 91NCT05139810
• Obatoclax for Systemic Mastocytosis: Complete Statistical AnalysisIndependent statistical analysis of Obatoclax for Systemic Mastocytosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00918931).Phase 2Results postedn = 3NCT00918931
• Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice: Complete Statistical AnalysisIndependent statistical analysis of Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 398NCT01524900
• Observational Trial With Enbrel: Complete Statistical AnalysisIndependent statistical analysis of Observational Trial With Enbrel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00488475).Phase NAResults postedn = 4,945NCT00488475
• Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 49NCT01294579
• Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…Phase 1/2Results postedn = 36NCT01515176
• Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 12NCT01716208
• Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01258933).Phase 2Results postedn = 4NCT01258933
• Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 99NCT01520922
• OLAIndependent statistical analysis of Oligonucleotide Ligation Assay (OLA) Resistance Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01898754).Phase NAResults postedn = 991NCT01898754
• OLEIndependent statistical analysis of Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 34NCT02613182
• OLE-IEDATIndependent statistical analysis of Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 104NCT03563053
• OLFUS-VIPESIndependent statistical analysis of Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 171NCT01955109

← All therapeutic areas